(Q39705813)

14 September 2017

1 reference

title

The metabolism and biopharmaceutics of spironolactone in man. (English)

1 reference

14 September 2017

Overdiek HW

1

1 reference

14 September 2017

Merkus FW

series ordinal

2

1 reference

14 September 2017

publication date

1 January 1987

1 reference

Reviews on drug metabolism and drug interactions

14 September 2017

published in

1 reference

14 September 2017

volume

5

1 reference

14 September 2017

issue

4

1 reference

14 September 2017

page(s)

273-302

1 reference

Spironolactone: Diversity in Metabolic Pathways

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Pharmacokinetic and Metabolic Fate of Potassium Canrenoate (SC-14266) in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

New insights into the pharmacokinetics of spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Elimination of canrenone in congestive heart failure and chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Spironolactone: Disposition, Metabolism, Pharmacodynamics, and Bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Spironolactone metabolism and gynaecomastia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Comparison of spironolactone tablet dosage forms in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Influence of food on the bioavailability of spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Binding of drugs to serum albumin (first of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Gynecomastia and semen abnormalities induced by spironolactone in normal men

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

SC 25152: A Potent Mineralocorticoid Antagonist with Reduced Affinity for the 5α-Dihydrotestosterone Receptor of Human and Rat Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

Interaction of Spironolactone and Digitalis with the 5α Dihydrotestosterone (DHT)1Receptor of Rat Ventral Prostate1

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.1987.5.4.273

10.1515/DMDI.1987.5.4.273

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference